Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18074272 | 0.80 | CASP3 (0.67) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL1430310 | 0.79 | CASP3 (0.65) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL1065287 | 0.79 | CASP3 (0.65) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL29620255 | 0.79 | KMT2A (0.56) | CA9ALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL1142116 | 0.78 | CASP3 (0.86) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL29724090 | 0.78 | CASP3 (0.86) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL20822267 | 0.78 | CASP3 (0.52) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL6386416 | 0.77 | SMN1; SMN2 (0.58) | CASP3ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL19154591 | 0.76 | CASP3 (0.56) | CASP3CA1CA2CA4CA9 | |
| SCHEMBL21997414 | 0.76 | CA1 (0.67) | CASP3CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148693-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148693-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10570144-B2 | Substituted ureas as prostaglandin EP4 receptor antagonists | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570144-B2 | Substituted ureas as prostaglandin EP4 receptor antagonists | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10239885-B1 | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist | AVISTA PHARMA SOLUTIONS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239885-B1 | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist | AVISTA PHARMA SOLUTIONS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148693-A1 | Chemical Compounds | PTGER4, PTGES, PTGER1 | CASP3 2242/4885CA1 4155/4885CA2 1427/4885 |
| US-10239885-B1 | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist | PTGER4, PTGER1, PTGER2 | CASP3 1672/4885CA1 4816/4885CA2 3142/4885 |
| US-10570144-B2 | Substituted ureas as prostaglandin EP4 receptor antagonists | PTGER4, PTGER1, PTGER2 | CASP3 2202/4885CA1 4523/4885CA2 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.